Why the study?
Do antithrombotic agents reduce platelet dense body secretion and aggregation in patients with acute ischemic stroke?
Do antithrombotic agents reduce platelet dense body secretion and aggregation in patients with acute ischemic stroke?
Answers are grounded in this paper and cite their sources.
Aspirin plus dipyridamole effectively inhibits platelet dense body secretion and aggregation in acute ischemic stroke, whereas heparin and warfarin do not.
We studied platelet function in whole blood, a situation that better reflects the in vivo state, from 85 patients with acute ischemic stroke and from 19 healthy controls. Patients receiving no antithrombotic drugs demonstrated increased platelet dense body secretion without an associated increase in platelet aggregation, thus raising the possibility that dense body secretion may be of separate importance in cerebral infarction. Our results also suggest that dense body secretion may occur independently of aggregation. Heparin and heparin plus warfarin were ineffective in reducing the high level of dense body secretion seen in acute cerebral infarction, whereas treatment with aspirin plus dipyridamole inhibited both dense body secretion and platelet aggregation. It seems worthwhile to investigate the usefulness of antiplatelet drugs in the treatment of acute ischemic stroke wherein clinical outcome is correlated with the extent of suppression of platelet dense body secretion.
No takes yet. Share an insight, caveat, or question.
Joseph et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: